Compare UTMD & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTMD | QNCX |
|---|---|---|
| Founded | 1978 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.4M | 167.0M |
| IPO Year | 1994 | 2019 |
| Metric | UTMD | QNCX |
|---|---|---|
| Price | $62.85 | $0.10 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 9.5K | ★ 67.7M |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.68 | N/A |
| Revenue | ★ $40,903,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.27 | $0.09 |
| 52 Week High | $68.71 | $4.55 |
| Indicator | UTMD | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 43.20 | 27.94 |
| Support Level | $60.00 | $0.09 |
| Resistance Level | $64.21 | $0.98 |
| Average True Range (ATR) | 1.67 | 0.02 |
| MACD | -0.61 | 0.09 |
| Stochastic Oscillator | 14.92 | 21.71 |
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.